Glucagon and type 2 diabetes: the return of the alpha cell. (Q38262673)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344790%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

review article

1 reference

title

Glucagon and type 2 diabetes: the return of the alpha cell (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344790%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

0 references

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344790%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344790%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344790%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Mikkel Christensen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344790%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Tina Vilsbøll

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344790%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

1 December 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344790%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

published in

Current diabetes report

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344790%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344790%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344790%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

555

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344790%20AND%20SRC:MED&resulttype=core&format=json

Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains

21 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Glucagon and the A cell: physiology and pathophysiology (first two parts).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

The essential role of glucagon in the pathogenesis of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Glucagon Receptor Knockout Prevents Insulin-Deficient Type 1 Diabetes in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Glucagon-stimulating activity of 20 amino acids in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Autonomic regulation of islet hormone secretion--implications for health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Somatostatin — both hormone and neurotransmitter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Alpha cell function in health and disease: influence of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

The contribution of incretin hormones to the pathogenesis of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Suppressive effect of secretin upon pancreatic alpha cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Physiological concentrations of cholecystokinin stimulate amino acid-induced insulin release in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Stimulation of glucagon secretion by gastric inhibitory polypeptide in patients with hepatic cirrhosis and hyperglucagonemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Insulin secretion in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Glucagon physiology and pathophysiology in the light of new advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Regulation of alpha-cell function by the beta-cell in isolated human and rat islets deprived of glucose: the "switch-off" hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes: documentation of the intraislet insulin hypothesis in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Autonomic nervous control of the endocrine secretion from the isolated, perfused pig pancreas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Regulation of glucagon secretion by incretins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

The incretin system and its role in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Glucagon antagonism as a potential therapeutic target in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Secretory effects of gastric inhibitory polypeptide on the isolated perfused porcine pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0555-4

Pancreatic alpha- and beta-cell responses to GIP infusion in normal man

21 January 2018

1 reference

12 December 2020

Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus

1 reference

12 December 2020

Dose-response for glucagonostatic effect of amylin in rats

1 reference

12 December 2020

Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms

1 reference

12 December 2020

Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals

1 reference

12 December 2020

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

1 reference

12 December 2020

Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction

1 reference

12 December 2020

Impact of lack of suppression of glucagon on glucose tolerance in humans

1 reference

12 December 2020

Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas

1 reference

12 December 2020

Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39

1 reference

12 December 2020

Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM

1 reference

12 December 2020

Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8

1 reference

12 December 2020

Glucagon-Like Peptide I and Glucose-Dependent Insulinotropic Polypeptide Stimulate Ca2+-Induced Secretion in Rat -Cells by a Protein Kinase A-Mediated Mechanism

1 reference

12 December 2020

Pancreatic polypeptide, glucagon and insulin secretion from the isolated perfused canine pancreas

1 reference

12 December 2020

Selective neurohormonal interactions in islet cell secretion in the isolated perfused human pancreas

1 reference

12 December 2020

Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus

1 reference

12 December 2020

10.1007/S11892-014-0555-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344790%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

21 February 2020

1023952105

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344790%20AND%20SRC:MED&resulttype=core&format=json